<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1409234212
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1980
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PRIMOLUT N TAB 5 MG
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NORETHISTERONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        18.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAYER WEIMAR GmbH UND CO. KG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAYER WEIMAR GmbH UND CO. KG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 392]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-KAMAL IMPORT OFFICE CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAYER  AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03AC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        G03DC02
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Primolut N contains norethisterone, which belongs to a group of medicines<br />called progestogens, which are female hormones.<br />Primolut N can be used in several different circumstances:</p><p><strong>▸</strong> to treat irregular, painful or heavy periods<br /><strong>▸ </strong>to treat endometriosis (where tissue from the lining of the womb is present in<br />places where it is not normally found)<br /><strong>▸ </strong>to treat premenstrual syndrome (also known as premenstrual tension, PMS<br />or PMT)<br /><strong>▸ </strong>to delay periods</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>▸ </strong>Your doctor will discuss your medical and family history with you. Your doctor<br />will also need to check your blood pressure and make sure you are not pregnant.<br />You may also need additional checks, such as a breast examination,<br />that will be specific to your medical needs and/or concerns.<br /><strong>Do not take Primolut N:</strong><br /><strong>▸ if you are allergic</strong> to norethisterone or any of the other ingredients of this<br />medicine (listed in section 6).<br /><strong>▸ if you are pregnant </strong>or if you think you might be pregnant<br /><strong>▸ if you are breast-feeding</strong><br />or:<br /><strong>▸ if you have</strong> ever had a problem with your blood circulation. This includes a<br /><strong>blood clot</strong> (thrombosis) in the legs (deep vein thrombosis), lungs (pulmonary<br />embolism), heart<strong> (heart attack),</strong> brain<strong> (stroke)</strong> or any other parts of the body<br /><strong>▸ if you have any symptoms of a blood clot, such as chest pain, unexplained<br />and often sudden shortness of breath and/or cough</strong><br /><strong>▸ if you have any</strong> condition which makes you <strong>more at risk of a blood clot</strong><br />(thrombosis)<br /><strong>▸ if you have </strong>ever suffered <strong>migraine</strong> with visual disturbance<br /><strong>▸ if you have</strong> (or are recovering from) a<strong> liver disease</strong> and the blood tests show<br />that your liver is not yet working normally<br /><strong>▸ if you have </strong>(or have ever had) <strong>liver tumours</strong><br /><strong>▸ if you have diabetes</strong> with damaged b<strong>lood vessels</strong><br /><strong>▸ if you have any type of cancer which might be made worse by exposure</strong><br /><strong>to female sex hormones</strong> (including breast cancer)<br /><strong>▸ if you have</strong> problems with <strong>genital bleeding</strong> for which the cause is not yet<br />known<br /><strong>▸ if you have</strong> a condition called <strong>endometrial hyperplasia</strong> which has not been<br />treated.<br />Do not use Primolut N if you have hepatitis C and are taking the medicinal<br />products containing ombitasvir/paritaprevir/ritonavir and dasabuvir (see also in<br />section &ldquo;Other medicines and Primolut N&rdquo;).<br />In addition, do not take Primolut N if you have had any of the following<br />conditions when you were pregnant:<br /><strong>▸ </strong>yellowing of the skin (idiopathic jaundice of pregnancy)<br /><strong>▸ </strong>itching of the whole body (pruritus of pregnancy)</p><p><strong>&rarr; Tell your doctor</strong> if any of these apply to you and do not take Primolut N.<br /><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking Primolut N<br /><strong>▸ </strong>if you smoke<br /><strong>▸ </strong>if you have<strong> diabetes</strong> (metabolic disease with elevated blood sugar levels). PrimolutN</p><p>can produce changes in blood sugar levels. If you are diabetic, your<br />doctor will check your blood sugar before starting treatment and regularly<br />during treatment<br /><strong>▸ </strong>if you are overweight <strong>(BMI &ge; 30 kg/m2)</strong><br /><strong>▸ </strong>if you have <strong>high blood pressure</strong><br /><strong>▸ </strong>if you have a<strong> heart valve disorder</strong> or a certain<strong> heart rhythm disorder </strong>(heart<br />problems)<br /><strong>▸ </strong>if you have had a <strong>thrombosis/embolism</strong> or anyone in your close family has<br />had a thrombosis, a heart attack or a stroke at a young age<br /><strong>▸ </strong>if you suffer from m<strong>igraine, asthma, or kidney problems</strong><br /><strong>▸ </strong>if you suffer from epilepsy (see &ldquo;Other medicines and Primolut N&rdquo;)<br /><strong>▸ </strong>if you have an<strong> inflammation of your veins</strong> (superficial phlebitis)<br /><strong>▸ </strong>if you have <strong>varicose veins</strong><br /><strong>▸ </strong>if anyone in your immediate family has had <strong>breast cancer</strong><br /><strong>▸ </strong>if you have previously had a condition called <strong>chloasma </strong>where the skin on<br />your face may develop brownish blotches. You may be advised to avoid exposure<br />to the sun and to ultraviolet light while you are taking Primolut N<br /><strong>▸ </strong>if you have previously suffered from <strong>depression</strong><br /><strong>▸</strong>if you or someone in your close family has ever had<strong> high blood levels of</strong><br /><strong>cholesterol or triglycerides</strong> (fatty substances). High blood levels of fatty<br />substances have been associated with an increased risk of developing pancreatitis<br />(inflammation of pancreas)<br /><strong>▸ </strong>if you have a disease of the liver or gall bladder<br /><strong>▸ </strong>if you have certain rare medical conditions such as systemic lupus erythematosus<br />(SLE), sickle cell disease, Crohn&rsquo;s disease or ulcerative colitis<br /><strong>▸ </strong>if you have haemolytic uremic syndrome (HUS)<br /><strong>▸ </strong>if you have a condition that occurred for the first time or worsened during<br />pregnancy or previous use of sex hormones (e.g. hearing loss, porphyria, or<br />Sydenham&rsquo;s chorea)<br /><strong>▸ </strong>if you have <strong>hereditary angioedema.</strong> Consult your doctor immediately if<br />you experience symptoms of angioedema such as swollen face, tongue or<br />throat, and/or difficulty swallowing, or hives, together with difficulty breathing.<br />Products containing oestrogens may induce or worsen symptoms of<br />angioedema<br /><strong>▸ </strong>if you have an intolerance to some types of sugar <strong>(galactose intolerance,<br />Lapp lactase deficiency or glucose-galactose malabsorption)</strong><br /><strong>▸ </strong>if you are using other medications as mentioned in &ldquo;Other Medicines and<br />Primolut N&rdquo;.<br /><strong>&rarr; Tell your doctor</strong> before you take Primolut N if any of these applies to you.<br />Also tell your doctor if any of these conditions develop or worsen while you<br />are taking Primolut N, because you may need to stop taking it.<br /><strong>Primolut N and blood clots:</strong><br />The main ingredient in Primolut N (progestogen) is partly converted into<br />oestrogen so you should also consider the general warnings given for combined<br />oral contraceptive pills (&ldquo;the Pill&rdquo;).<br />Do not take Primolut N if you have a <strong>blood clot </strong>or have any medical condition<br />which makes you more at risk of developing clots.<br />The risk of blood clots occurring in the veins and arteries is slightly greater in</p><p>women who take the combined oral contraceptive pill than in women who<br />don&rsquo;t. People do not always fully recover from such blood clots, which can cause<br />strokes, heart attacks and bleeding into the brain (subarachnoid haemorrhage).<br />In very rare cases these blood clots can be fatal.<br /><strong>You are more at risk of having a blood clot:</strong><br /><strong>▸ </strong>as you get older<br /><strong>▸ </strong>if you&rsquo;re off your feet for a long time because of major surgery, injury or illness.<br /><strong>▸ </strong>if you smoke<br /><strong>▸ </strong>if you or any of your close family have had blood clots<br /><strong>▸ </strong>if you are overweight (BMI &ge; 30 kg/m2)<br /><strong>▸ </strong>if you have a disorder of blood fat (lipid) metabolism<br /><strong>▸ </strong>if you have a blood disorder<br /><strong>▸ </strong>if you have high blood pressure<br /><strong>▸ </strong>if you suffer from migraines<br /><strong>▸ </strong>if you have a heart valve disorder or a particular type of irregular heartbeat<br />(atrial fibrillation)<br /><strong>▸ </strong>if you have recently had a baby<br /><strong>▸ </strong>if you have diabetes<br /><strong>▸ </strong>if you have certain medical conditions such as systemic lupus erythematosus<br />(SLE), sickle cell disease, Crohn&rsquo;s disease or ulcerative colitis<br /><strong>&rarr; Tell your doctor if any of these apply to you</strong>. Taking Primolut N may add<br />to this risk so it may not be suitable for you.<br />To reduce the risk of blood clots, treatment with Primolut N must be stopped:<br /><strong>▸ </strong>six weeks before any planned major operation<br /><strong>▸ </strong>before any surgery to the legs<br /><strong>▸ </strong>before medical treatment for varicose veins<br /><strong>▸ </strong>if you are going to be immobilised for a long time (e.g. if you need bed-rest<br />after an accident or operation, or if you have a plaster cast on a broken leg)<br /><strong>Signs of a blood clot include:</strong><br /><strong>▸ </strong>a migraine for the first time or one that is worse than normal<br /><strong>▸ </strong>unusually frequent or severe headaches<br /><strong>▸ </strong>any sudden changes to your eyesight (such as loss of vision or blurred vision)<br /><strong>▸ </strong>any sudden changes to your hearing, speech, sense of smell, taste or touch<br /><strong>▸ </strong>pain or swelling in your leg<br /><strong>▸ </strong>stabbing pain when you breathe<br /><strong>▸ </strong>coughing for no apparent reason<br /><strong>▸ </strong>breathlessness<br /><strong>▸ </strong>pain and tightness in the chest<br /><strong>▸ </strong>sudden weakness or numbness in one side or part of your body<br /><strong>▸ </strong>dizziness or fainting.<br /><strong>&rarr; See a doctor as soon as possible if you notice any possible signs of blood<br />clot</strong>. Do not take any more Primolut N until your doctor says you can.<br /><strong>Primolut N and cancer</strong><br />If you have <strong>breast cancer</strong>, or have had it in the past, you should not take<br />combined oral contraceptives (the Pill). The Pill slightly increases your risk of<br />breast cancer. This risk goes up the longer you&rsquo;re on it, but returns to normal<br />within about 10 years of stopping it. Because breast cancer is rare in women<br />under the age of 40, the extra cases of breast cancer in current and recent Pill<br />users is small. For example:<br /><strong>▸ </strong>Of 10,000 women who have <strong>never taken the Pill</strong>, about 16 will have breast<br />cancer by the time they are 35 years old.<br /><strong>▸ </strong>Of 10,000 women who <strong>take the Pill for 5 years in their early twenties,</strong><br />about 17&ndash;18 will have breast cancer by the time they are 35 years old.<br /><strong>▸ </strong>Of 10,000 women who have never taken the Pill, about 100 will have breast<br />cancer by the time they are 45 years old.<br /><strong>▸ </strong>Of 10,000 women who <strong>take the Pill for 5 years in their early thirties</strong>, about<br />110 will have breast cancer by the time they are 45 years old.<br /><strong>Your risk of breast cancer is higher if:</strong><br /><strong>▸ </strong>you have a close relative (mother, sister or grandmother) who has had breast<br />cancer<br /><strong>▸ </strong>you are overweight (BMI &ge; 30 kg/m2)<br /><strong>&rarr; See a doctor as soon as possible if you notice any changes in your</strong><br /><strong>breasts</strong>, such as dimpling of the skin, changes in the nipple or any lumps<br />you can see or feel.<br />Very rarely, the Pill has been linked with some forms of liver cancer in women<br />who take it for a long time. These may lead to bleeding in the abdomen.<br />Taking the Pill has also been linked to liver diseases, such as jaundice and noncancerous<br />liver tumours, but this is rare.<br /><strong>&rarr; See a doctor as soon as possible if you get severe pain in your stomach<br />that does not go away, or yellow skin or eyes (jaundice)</strong>. You may need<br />to stop taking Primolut N.<br /><strong>Other medicines and Primolut N<br />Tell your doctor</strong> if you are taking, have recently taken or might take any other<br />medicines.<br />Some medicines:<br /><strong>▸ </strong>can have an influence on the blood levels of Primolut N.<br /><strong>▸ </strong>can make it less effective.<br />&nbsp;<strong>▸ </strong>can cause unexpected bleeding<br />These include:<br /><strong>▸ </strong>medicines used for the treatment of:</p><ul><li>epilepsy (e.g. primidone, phenytoin, barbiturates, carbamazepine,</li><li>oxcarbazepine, topiramate, felbamate)</li><li>tuberculosis (e.g. rifampicin)</li><li>fungal infections (griseofulvin, azole antifungals, e.g. itraconazole, voriconazole, fluconazole)</li><li>HIV and Hepatitis C Virus infections (so-called protease inhibitors and</li></ul><p>non-nucleoside reverse transcriptase inhibitors, e.g. ritonavir, nevirapine, efavirenz)</p><ul><li>bacterial infections (macrolide antibiotics, e.g. clarithromycin, erythromycin)</li><li><strong>&nbsp;</strong>certain heart diseases, high blood pressure (calcium channel blockers, e.g.verapamil, diltiazem)</li><li>arthritis, arthrosis (etoricoxib)</li><li>high blood pressure in the blood vessels in the lung (bosentan)</li></ul><p><strong>▸ </strong>the herbal remedy St. John&rsquo;s wort (primarily used for the treatment of depressive<br />moods)<br /><strong>▸ </strong>grapefruit juice<br />Primolut N may influence the effect of other medicines, e.g.:<br /><strong>▸ </strong>medicines containing ciclosporine<br /><strong>▸ </strong>the anti-epileptic lamotrigine (this could lead to an increased frequency of<br />seizures)<br /><strong>▸ </strong>theophylline (used to treat breathing problems)<br /><strong>▸ </strong>tizanidine (used to treat muscle pain and/or muscle cramps)<br />Do not use Primolut N if you have Hepatitis C and are taking the medicinal<br />products containing ombitasvir/paritaprevir/ritonavir and dasabuvir as this may<br />cause increases in liver function blood test results (increase in ALT liver enzyme).<br />Primolut N can be restarted approximately 2 weeks after completion of this<br />treatment. See section &ldquo;Do not use Primolut N&rdquo;.<br />Taking Primolut N can affect the results of some blood and urine tests. Tell your<br />doctor that you are taking Primolut N if you are asked to provide a blood or<br />urine sample.<br /><strong>Other things you should know:</strong><br />Once you have finished taking a course of Primolut N, you will usually have a<br />menstrual bleed (period) 2-3 days after taking your last tablet. If you do not<br />have a period, you must make sure that you are not pregnant before taking any<br />more tablets.<br /><strong>Pregnancy and breast-feeding<br />Do not take Primolut N if you are pregnant or breast-feeding.</strong> If you think<br />you may be pregnant or are planning to have a baby, ask your doctor for advice<br /><strong>before taking this medicine.</strong><br />Driving and using machines<br />Primolut N is unlikely to affect your ability to drive or use machines.<br /><strong>Primolut N contains lactose</strong><br />If you have been told by your doctor that you have an intolerance to some<br />sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you.<br />Check with your doctor or pharmacist if you are not sure.<br />The number of tablets that you need to take and the number of days per month<br />when you need to take them will depend on why the doctor has prescribed<br />Primolut N. A common dosage would be 2-3 tablets each day. For some<br />conditions Primolut N has to be taken every day, but this is not always the case.<br />Ask your doctor or pharmacist, if you are not sure about the number of tablets<br />that you need to take, when they should be taken or how long you should take<br />them for.<br />Swallow the tablets whole with a drink of water.<br /><strong>If you take more Primolut N than you should</strong><br />Taking too many tablets is unlikely to cause serious problems. If you take too<br />many, contact your doctor who will tell you what to do.<br /><strong>If you forget to take Primolut N</strong><br />If you forget a dose, wait until it is time to take the next prescribed dose. Do not<br />take the missed dose. If you are worried, contact your doctor or pharmacist.<br />If you have any further questions on the use of this medicine, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody<br />gets them.<br /><strong>Reasons for stopping Primolut N immediately:</strong><br />Stop taking Primolut N and speak to your doctor immediately if you experience<br />any of the following:<br /><strong>▸ </strong>migraine for the first time<br /><strong>▸ </strong>unusually bad headaches, occurring more often than before<br /><strong>▸ </strong>sudden changes to your eyesight, hearing or speech<br /><strong>▸ </strong>sudden changes to your senses of smell, taste or touch<br /><strong>▸ </strong>symptoms of blood clot formation or symptoms of inflammation of the veins<br />combined with the formation of blood clots (thrombophlebitis):</p><ul><li>&nbsp;unusual pains in your leg(s)</li><li>unusual swelling of your arms or legs</li><li>sharp pains in your chest or sudden shortness of breath</li><li>crushing pains or feelings of heaviness or tightness in your chest</li><li>coughing for no apparent reason</li><li>one side of your body suddenly becoming very weak or numb</li></ul><p><strong>Primolut N must also be stopped immediately if:</strong><br /><strong>▸ </strong>you become pregnant<br /><strong>▸ </strong>you develop jaundice or other liver problems<br /><strong>▸ </strong>you develop itching (pruritus)<br /><strong>▸ </strong>your doctor finds that your blood pressure is too high<br /><strong>General side effects:</strong><br />Side effects that have been reported with Primolut N are listed below according<br />to the frequency with which they occur.<br /><strong>Very common side effects </strong>(These may affect more than 1 in 10 people)<br /><strong>▸ </strong>Vaginal bleeding, including spotting.<br /><strong>▸ </strong>Periods that are much shorter than normal and where blood flow is reduced.<br /><strong>Common side effects</strong> (These may affect up to 1 in 10 people)<br /><strong>▸ </strong>Headache<br /><strong>▸ </strong>Feeling sick (nausea)<br /><strong>▸ </strong>Absence of a period<br /><strong>▸ </strong>Swelling<br /><strong>Uncommon side effects</strong> (These may affect up to 1 in 100 people)<br /><strong>▸ </strong>Migraine<br /><strong>Rare side effects </strong>(These may affect up to 1 in 1,000 people)<br /><strong>▸ </strong>Allergic reactions including skin rash or &ldquo;hives&rdquo;<br /><strong>Very rare side effects</strong> (These may affect up to 1 in 10,000 people)<br /><strong>▸ </strong>Visual disturbances<br /><strong>▸ </strong>Difficulty in breathing<br /><strong>Other side effects</strong> (Frequency not known: frequency cannot be estimated from<br />the available data)<br /><strong>▸ </strong>Worsening of depression<br /><strong>▸ </strong>Dizziness<br /><strong>▸ </strong>Abdominal pain<br /><strong>▸ </strong>Jaundice<br /><strong>▸ </strong>Cholestasis<br /><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor or pharmacist. This includes any<br />possible side effects not listed in this leaflet.. By reporting side effects you can<br />help provide more information on the safety of this medicine.<br /><strong>To report any side effect(s):</strong><br />The National Pharmacovigilance and Drug Safety Centre (NPC).<br />Fax: + 966 - 11 - 205 - 7662.<br />Call NPC at +966 - 11 - 2038222,<br />Ext.: 2317 - 2356 - 2340.<br />Reporting hotline: 19999.<br />E - mail: npc.drug@sfda.gov.sa.<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Store in the original carton. Store below 30&deg;C.<br />Do not use this medicine after the expiry date which is stated on both the outer<br />carton and on each blister strip of tablets after EXP. The expiry date refers to the<br />last day of that month.<br />Do not throw away any medicines via wastewater or household waste. Ask your<br />pharmacist how to throw away medicines you no longer use. These measures<br />will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each tablet contains 5 mg of the active ingredient, norethisterone. The other<br />ingredients are lactose, maize starch and magnesium stearate (E572).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                White, cross-scored tablets on one side with an emblem ‘AN’ in a hexagon on the
other side.
Packed in 2 x 15 tablets in a blister pack (PVC/Aluminum).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer</strong><br />Bayer Weimar GmbH and Co. KG<br />99427 Weimar, Germany.<br /><strong>a subsidiary of</strong><br />Bayer AG,<br />Kaiser-Wilhelm-Allee 1<br />51373 Leverkusen, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in December, 2018.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي بريمولوت ن على نوريثيستيرون والذي ينتمي إلى مجموعة من الأدوية تُعرف باسم البروجيستوجينات، وهي هرمونات أنثوية.</p><p dir="RTL">من الممكن استخدام بريمولوت ن في العديد من الحالات المختلفة:</p><ul dir="rtl"><li>لعلاج الدورات الشهرية غير المنتظمة أو المؤلمة أو الثقيلة</li><li>لعلاج الانتباذ البطاني الرحمي (حيث تكون أنسجة من بطانة الرحم موجودة في أماكن لا تتواجد بها عادة)</li><li>لعلاج المتلازمة السابقة للحيض (والتي تعرف أيضا بالتوتر السابق للحيض أو PMS أو PMT)</li><li>لتأخير الدورات الشهرية</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li>سوف يقوم طبيبك بمناقشة تاريخك الطبي والعائلي معك. سوف يحتاج طبيبك أيضا إلى فحص ضغط دمك والتأكد من أنك لست حاملا. كما قد تحتاجين إلى عمل فحوصات إضافية، مثل فحص الثدي، والذي سيكون محددا بحسب احتياجاتك و/أو مخاوفك الطبية.</li></ul><p dir="RTL"><strong>لا تتناولي بريمولوت ن:</strong></p><ul dir="rtl"><li>إذا كنت <strong>مصابة بحساسية</strong> تجاه نوريثيستيرون أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</li><li>إذا كنت حاملا أو تعتقدين أنك قد تكونين حاملا</li><li>إذا كنت <strong>ترضعين رضاعة طبيعية</strong>.</li></ul><p dir="RTL"><strong>أو:</strong></p><ul dir="rtl"><li>إذا كنت قد عانيت في أي وقت مضى من مشكلة في الدورة الدموية. ويشتمل هذا على <strong>تجلط الدم</strong> (تخثر الدم) في الساقين (تخثر الأوردة العميقة) أو الرئتين (انسداد رئوي) أو القلب (<strong>نوبات قلبية</strong>) أوالدماغ (<strong>سكتة دماغية</strong>) أو أي أجزاء أخرى من الجسم</li><li>إذا كان لديك أي من<strong> أعراض تجلط الدم</strong>، مثل<strong> آلام الصدر</strong> أو <strong>ضيق التنفس غير المبرر وغالبا ما يكون مفاجئ </strong>و/أو <strong>السعال</strong></li><li>إذا كنت مصابة بأي مرض يجعلك <strong>أكثر عرضة لتجلط الدم</strong> (تخثر الدم)</li><li>إذا كنت قد عانيت في أي وقت مضى من <strong>صداع نصفى </strong>(شقيقة)، مصحوبا باضطرابات بصرية</li><li>إذا كنت مصابة (أو تتعافي من) <strong>مرض في الكبد</strong> وفحوصات الدم قد أظهرت أن الكبد ما زال لا يعمل بالشكل الطبيعي</li><li>إذا كنت مصابة (أو قد أُصبت من قبل) <strong>بأورام في الكبد</strong></li><li>إذا كنت مصابة<strong> بمرض السكر </strong>مع تلف في الأوعية الدموية</li><li>إذا كنت مصابة <strong>بأي نوع من أنواع السرطان والذي من الممكن أن يصبح أسوأ عند التعرض لهرمونات أنثوية</strong> (بما في ذلك سرطان الثدي)</li><li>إذا كان لديك مشاكل<strong> نزيف من الأعضاء التناسلية</strong> لم يُعرف سببها بعد</li><li>إذا كنت مصابة بحالة تعرف <strong>بفرط تنسج بطانة الرحم</strong> والتي لم يتم علاجها بعد.</li></ul><p dir="RTL">لا تستخدمي بريمولوت ان إذا كنت مصابة بالتهاب الكبد الفيروسي ج وكنت تتناولين المستحضرات الطبية التي تحتوي على أمبيتاسفير \ باريتابريفير \ ريتونافير \ وداسابوفير (انظري أيضاً في الجزء &laquo;أدوية أخرى وبريمولوت ن&raquo;).</p><p dir="RTL">بالإضافة إلى ذلك، لا تتناولي بريمولوت ن إذا كنت قد أصبت بأي من الحالات التالية أثناء حملك:</p><ul dir="rtl"><li>اصفرار لون الجلد (<strong>يرقان الحمل مجهول السبب</strong>)</li><li>حكة في جميع أنحاء الجسم (<strong>حكة الحمل</strong>)</li></ul><p dir="RTL"><strong>أخبري طبيبك</strong> إذا كان أيا من هذه الأعراض ينطبق عليك و<strong>لا تتناولي بريمولوت ن</strong></p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدثي مع طبيبك أو الصيدلي قبل تناول بريمولوت ن</p><ul dir="rtl"><li>إذا كنت<strong> تدخنين</strong></li><li>إذا كنت مصابة <strong>بمرض السكر</strong> (من أمراض التمثيل الغذائي الذي يسبب مستويات مرتفعة من السكر في الدم). من الممكن أن يحدث بريمولوت ن تغيرات في مستويات السكر في الدم. إذا كنت مصابة بمرض السكر، سوف يقوم طبيبك بفحص السكر في الدم قبل بدء العلاج وبشكل منتظم أثناء العلاج.</li><li>إذا كنت شديدة البدانة (<strong>مؤشر كتلة الجسم &ge; 30 كجم / م</strong><sup>2</sup>).</li><li>إذا كنت مصابة<strong> بارتفاع ضغط الدم</strong></li><li>إذا كنت مصابة <strong>باضطراب في صمام القلب</strong> أو ب<strong>اضطراب معين في ضربات القلب</strong> (مشاكل في القلب)</li><li>إذا كنت قد أُصبت من قبل <strong>بجلطة / انسداد</strong> أو إذا كان أي شخص من عائلتك المقربة قد أصيب بجلطة أو أزمة قلبية أو سكتة دماغية في سن صغير.</li><li>إذا كنت تعانين من<strong> الصداع النصفي</strong> (الشقيقة) أو <strong>الربو أو مشاكل في الكلى</strong></li><li>إذا كنت تعانين من<strong> الصرع</strong> (انظري &laquo;الأدوية الأخرى وبريمولوت ن&raquo;)</li><li>إذا كنت مصابة <strong>بالتهاب في الأوردة </strong>(التهاب وريدي سطحي)</li><li>إذا كنت مصابة<strong> بالدوالي</strong></li><li>إذا كان أي من أفراد أسرتك المقربين مصاب <strong>بسرطان الثدي</strong></li><li>إذا كنت قد أصبت من قبل بحالة تسمى <strong>الكلف</strong> حيث قد تظهر بقع بنية على بشرة وجهك. قد ينصحك طبيبك بتجنب التعرض لضوء الشمس والأشعة فوق البنفسجية أثناء تناولك بريمولوت ن.</li><li>إذا كنت قد عانيت مسبقا من <strong>الاكتئاب</strong></li><li>إذا كنت قد أُصبت أنت أو أي من أفراد عائلتك المقربين <strong>بارتفاع مستوى الكولسترول في الدم</strong> أو<strong> الدهون الثلاثية</strong> (المواد الدهنية). ارتبط ارتفاع مستوي الدم من المواد الدهنية مع زيادة خطر الإصابة بالتهاب البنكرياس (التهاب البنكرياس)</li><li>إذا كنت مصابة<strong> بمرض في الكبد أو المرارة</strong></li><li>إذا كنت مصابة بأحد الحالات الطبية النادرة مثل <strong>الذئبة الحمامية الجهازية أو مرض فقر الدم المنجلي أو مرض كرون أو التهاب القولون التقرحي</strong></li><li>إذا كنت مصابة <strong>بمتلازمة انحلال الدم اليوريمية</strong></li><li>إذا كنت مصابة بحالة حدثت لأول مرة أو ساءت أثناء الحمل أو أثناء استخدام سابق لأدوية تحتوي على هرمونات تناسلية (مثل<strong> فقدان السمع</strong>، أو<strong> البورفيريا</strong>، أو <strong>رقص سيدنهام</strong>)</li><li>إذا كنت مصابة <strong>بوذمة وعائية وراثية</strong>. استشيري طبيبك على الفورا إذا أصبت بأعراض الوذمة الوعائية مثل تورم الوجه أو اللسان أو الحلق و/ أو صعوبة في البلع أو شرى مع صعوبة في التنفس. المنتجات التي تحتوي على الإستروجينات من الممكن أن تحفز أو تفاقم أعراض الوذمة الوعائية</li><li>إذا كنت مصابة <strong>بعدم تحمل لبعض أنواع السكر</strong> (عدم تحمل الجالاكتوز، نقص اللاكتاز لاب أو سوء امتصاص الجلوكوز والجالاكتوز)</li><li>إذا كنت تستخدمين أدوية أخرى كما هو موضح في &laquo;الأدوية الأخرى وبريمولوت ن).</li></ul><p dir="RTL"><strong>أخبري طبيبك</strong> قبل تناول بريمولوت ن إذا كان أي من هذه الأعراض ينطبق عليك<strong>. </strong>أخبري طبيبك أيضا إذا تطورت أي من هذه الحالات أو أصبحت أسوأ أثناء تناول بريمولوت ن، لأنك قد تحتاجين إلى التوقف عن تناوله.</p><p dir="RTL"><strong>بريمولوت ن وجلطات الدم:</strong></p><p dir="RTL">إن المكون الرئيسي في بريمولوت ن (بروجيستوجين) يتحول جزئيا إلى إستروجين، لذلك ينبغي أيضا أن تأخذي في الاعتبار التحذيرات العامة المتبعة مع حبوب منع الحمل التي تؤخذ عن طريق الفم المركبة (&laquo;الحبة&raquo;).</p><p dir="RTL">لا تتناولي بريمولوت ن إذا كنت مصابة <strong>بجلطة دموية</strong> أو كنت مصابة بأي حالة طبيبة تجعلك أكثر عرضة للإصابة بالجلطات.</p><p dir="RTL">إن خطر حدوث جلطات دموية في الأوردة والشرايين يكون أعلى قليلا في السيدات اللاتي يتناولن حبوب منع حمل فموية مركبة عن أولئك اللاتي لا يتناولنها. ولا يتعافى الناس دائما من مثل هذه الجلطات الدموية، مما قد يؤدي إلى حدوث سكتة دماغية، ونوبات قلبية ونزيف في المخ (نزف تحت العنكبوتية). وفي حالات نادرة جدا، من الممكن أن تكون هذه الجلطات الدموية مميتة.&nbsp;</p><p dir="RTL"><strong>أنت تصبحين أكثر عرضة لخطر الإصابة بجلطة دموية:</strong></p><ul dir="rtl"><li>مع التقدم في السن</li><li>إذا كنت لا تقفين على قدميك لفترة طويلة بسبب جراحة كبرى أو مرض أو إصابة.</li><li>إذا كنت تدخنين</li><li>إذا كنت قد أصبت أنت أو أي من أفراد عائلتك المقربين بجلطات دموية</li><li>إذا كنت شديدة البدانة (مؤشر كتلة الجسم &ge; 30 كجم / م<sup>2</sup>).</li><li>إذا كنت مصابة باضطراب في أيض الدهون في الدم</li><li>إذا كنت مصابا باضطراب في الدم</li><li>إذا كنت مصابة بارتفاع ضغط الدم</li><li>إذا كنت تعانين من الصداع النصفي (الشقيقة)</li><li>إذا كنت مصابة باضطراب في صمام القلب أو نوع معين من عدم انتظام ضربات القلب (الرجفان الأذيني)</li><li>إذا كنت قد أنجبت طفلا مؤخرا</li><li>إذا كنت مصابة بمرض السكر</li><li>إذا كنت مصابة بحالات طبية محددة مثل الذئبة الحمامية الجهازية أو مرض فقر الدم المنجلي أو مرض كرون أو التهاب القولون التقرحي</li></ul><p dir="RTL"><strong>أخبري طبيبك إذا كان أي من هذه الأعراض ينطبق عليك.</strong> إن تناول بريمولوت ن قد يزيد من هذا الخطر لذلك فقد يكون غير مناسب لك.<strong> </strong></p><p dir="RTL">لتقليل خطر التعرض لجلطات دموية، ينبغي إيقاف العلاج ببريمولوت ن:</p><ul dir="rtl"><li>لمدة ستة أسابيع قبل اجراء أي جراحة كبرى مخطط لها</li><li>قبل إجراء أي جراحة في الساقين</li><li>قبل العلاج الطبي لدوالي الأوردة</li><li>إذا كنت ستتوقفين عن الحركة لفترة زمنية طويلة (مثل إذا كنت تحتاجين للراحة في الفراش بعد التعرض لحادث أو جراحة، أو إذا كانت ساقك مكسورة وموضوعة في الجبس)</li></ul><p dir="RTL"><strong>علامات الجلطة الدموية تشمل:</strong></p><ul dir="rtl"><li>صداع نصفي (شقيقة) لأول مرة أو أن يكون أسوأ من المعتاد</li><li>صداع متكرر أو شديد بشكل غير عادي</li><li>أي تغيرات مفاجئة في الإبصار (مثل فقدان البصر أو عدم وضوح الرؤية)</li><li>أي تغيرات مفاجئة في السمع أو النطق أو حاسة الشم أو التذوق أو اللمس لديك</li><li>ألم أو تورم في ساقك</li><li>ألم شديد عند التنفس</li><li>السعال بدون سبب واضح</li><li>ضيق التنفس</li><li>ألم وضيق في الصدر</li><li>ضعف أو خدر مفاجئ في أحد الجانبين أو في جزء من جسمك</li><li>دوخة أو إغماء</li></ul><p dir="RTL"><strong>راجعي طبيبك بمجرد ملاحظة أي علامات محتملة لتجلط الدم.</strong> لا تتناولي بريمولوت ن حتى يخبرك طبيبك أن بإمكانك ذلك.<strong> </strong></p><p dir="RTL"><strong>بريمولوت ن والسرطان </strong></p><p dir="RTL">إذا كنت مصابة بسرطان الثدي أو كنت قد أصبت به في الماضي، فلا ينبغي أن تتناولي أي أقراص منع حمل فموية مركبة (الحبة) إن الحبة تزيد من خطر إصابتك بسرطان الثدي. ويزداد هذا الخطر كلما زادت فترة تناولك لها، ولكنه يعود إلى الوضع الطبيعي في غضون نحو 10 سنوات من إيقافها. ولأن الإصابة بسرطان الثدي نادر الحدوث في السيدات تحت سن الـ40، فإن الحالات الإضافية من الإصابة بسرطان الثدي في المستخدمين الحاليين والحديثين للحبة صغيرة. على سبيل المثال:</p><ul dir="rtl"><li>من بين كل 10000 سيدة <strong>لم يتناولن الحبة أبدا</strong>، ستصاب نحو <strong>16</strong> منهن بسرطان الثدي مع بلوغهن سن 35 عاما.</li><li>من بين كل 10000 سيدة <strong>تناولن الحبة لمدة 5 سنوات في فترة أوائل العشرينات،</strong> ستصاب نحو<strong> 17 - 18</strong> سيدة منهن بسرطان الثدي مع بلوغهن سن 35 عاما.</li><li>من بين كل 10000 سيدة <strong>لم يتناولن الحبة أبدا</strong>، ستصاب نحو<strong> 100</strong> منهن بسرطان الثدي مع بلوغهن سن 45 عاما.</li><li>من بين كل 10000 سيدة <strong>تناولن الحبة لمدة 5 سنوات في فترة أوائل الثلاثينات</strong>، ستصاب نحو <strong>110</strong> سيدة منهن بسرطان الثدي مع بلوغهن سن 45 عاما.</li></ul><p dir="RTL"><strong>خطر إصابتك بسرطان الثدي سيكون أعلى إذا:</strong></p><ul dir="rtl"><li>كان لديك قريبة (أم أو أخت أو جدة) قد أُصيبت بسرطان الثدي.</li><li>كنت شديدة البدانة (<strong>مؤشر كتلة الجسم &ge; 30 كجم / م<sup>2</sup></strong>).</li></ul><p dir="RTL"><strong>راجعي طبيبك في أقرب فرصة ممكنة إذا لاحظت أي تغيرات في ثدييك،</strong> مثل ترصع الجلد أو تغيرات في الحلمة أو أي كتل يمكنك رؤيتها أو الاحساس بها<strong>.</strong></p><p dir="RTL">كما ارتبطت الحبة في حالات نادرة جدا ببعض أنواع سرطان الكبد في السيدات اللاتي يتناولنها لفترات طويلة. وقد يؤدي هذا إلى نزيف في البطن.</p><p dir="RTL">ارتبط تناول الحبة أيضا ببعض أمراض الكبد مثل اليرقان وأورام الكبد غير السرطانية، ولكن يحدث هذا في حالات نادرة.</p><p dir="RTL"><strong>راجعي طبيبك في أقرب فرصة ممكنة إذا أصبت بألم شديد لا يختفي في معدتك أو اصفرار في الجلد أو العينين (يرقان).</strong> قد تحتاجين للتوقف عن تناول بريمولوت ن.</p><p dir="RTL"><strong>الأدوية الأخرى وبريمولوت ن</strong></p><p dir="RTL"><strong>أخبري طبيبك</strong> إذا كنت تتناولين أو قد تناولت مؤخرا أو قد تتناولي أي أدوية أخرى.</p><p dir="RTL">بعض الأدوية</p><ul dir="rtl"><li>يمكن أن يكون لها تأثير على مستويات بريمولوت ن في الدم.</li><li>يمكن أن تجعل بريمولوت ن أقل فعالية.</li><li>يمكن أن تسبب نزيف غير متوقع.</li></ul><p dir="RTL">وتشمل هذه الأدوية على الآتي:</p><ul dir="rtl"><li>الأدوية المستخدمة لعلاج:</li></ul><p dir="RTL">&nbsp; &nbsp; &nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصرع (على سبيل المثال بريميدون، فينيتوين، الباربيتورات، كاربامازيبين، أوكسكاربازيبين، توبيراميت، فيلباميت)</p><p dir="RTL">&nbsp; &nbsp; &nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السل (على سبيل المثال ريفامبيسين)</p><p dir="RTL">&nbsp; &nbsp; &nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيروس العوز المناعي البشري والتهاب الكبد الفيروسي ج (ما يسمى مثبطات الأنزيم البروتيني ومثبطات منتسخة عكسية لا نيوكليوسيدية، على سبيل المثال ريتونافير، نيفاربين، إيفافيرينز)</p><p dir="RTL">&nbsp; &nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الفطرية (غريسيوفولفين، مضادات الفطريات من مجموعة الآزول، على سبيل المثال، إيتراكونازول، فوريكونازول، فلوكونازول)</p><p dir="RTL">&nbsp; &nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى البكتيرية (المضادات الحيوية من مجموعة الماكروليد، مثل كلاريثروميسين، إريثروميسين)</p><p dir="RTL">&nbsp; &nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أمراض القلب، ارتفاع ضغط الدم (حاصرات قنوات الكالسيوم، على سبيل المثال فيراباميل ، ديلتيازيم)</p><p dir="RTL">&nbsp; &nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل، الإصابة بإمراض غضروف المفصل (إيتوريكوكسيب)</p><p dir="RTL">&nbsp; &nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم في الأوعية الدموية في الرئة (بوسنتان)</p><ul dir="rtl"><li>العلاج بالأعشاب الطبية باستخدام نبتة سانت جون (تستخدم في المقام الأول لعلاج اكتئاب المزاج)</li><li>عصير الليمون الهندي (عصير جريب فروت)</li></ul><p dir="RTL">قد يؤثر بريمولوت ن على تأثير الأدوية الأخرى، على سبيل المثال:</p><ul dir="rtl"><li>أدوية تحتوي على سيكلوسبورين</li><li>لاموتريجين مضاد للصرع (وهذا يمكن أن يؤدي إلى زيادة معدل الإصابة بنوبات الصرع)</li><li>الثيوفيلين (يستخدم لعلاج مشاكل التنفس)</li><li>تيزانيدين (يستخدم لعلاج آلام العضلات و / أو تشنجات العضلات)</li></ul><p dir="RTL">لا تستخدم بريمولوت ن إذا كنت مصاباً بالتهاب الكبد الفيروسي ج وتتناول المستحضرات الدوائية التي تحتوي على أمبيتاسفير \ باريتابريفير \ ريتونافير \ وداسابوفير لأن ذلك قد يسبب زيادة في نتائج فحص الدم لقياس وظائف الكبد (زيادة في إنزيم الكبد المعروف باسم&nbsp; تحليل إنزيم ناقلة أمين الألانين). يمكن إعادة تناول بريمولوت ن (تكرار العلاج باستخدام بريمولوت ن) بعد حوالي أسبوعين من الانتهاء من تناول هذا العلاج. انظر الجزء &laquo;لا تستخدم بريمولوت ن&raquo;.</p><p dir="RTL">من الممكن أن يؤثر تناول بريمولوت ن على نتائج بعض فحوصات الدم والبول. أخبري طبيبك بأنك تتناولين بريمولوت ن إذا طٌلب منك تقديم عينة دم أو بول للفحص.</p><p dir="RTL"><strong>أشياء أخرى ينبغي أن تعرفينها:</strong></p><p dir="RTL">بمجرد الإنتهاء من تناول المقدار المحدد لك من بريمولوت نور، سيأتيك عادة نزيف الحيض (الدورة) بعد 2-3 أيام من تناول آخر قرص. إذا لم يكن لديك دورة شهرية، فيجب أن تتأكدي من أنك لست حاملا قبل تناول المزيد من الأقراص.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا تتناولي بريمولوت ن إذا كنت حاملا أو ترضعين رضاعة طبيعية. إذا كنت تعتقدين أنك قد تكونين حاملا أو تخططين لإنجاب طفل، استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المرجح أن يؤثر بريمولوت ن في قدرتك على القيادة أو استخدام الآلات.</p><p dir="RTL"><strong>بريمولوت ن يحتوي على لاكتوز</strong></p><p dir="RTL">إذا كان طبيبك قد أخبرك أنك مصابة بعدم تحمل لبعض أنواع السكر، فتحدثي مع طبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناولي هذا الدواء دائما كما أخبرك طبيبك بالضبط. يجب مراجعة طبيبك أو الصيدلي إذا لم تكوني متأكدة.</p><p dir="RTL">سيعتمد عدد الأقراص الذي ستحتاجين لتناوله وعدد الأيام في الشهر التي ستحتاجين لتناولهم فيه على السبب الذي من أجله قد وصف لك الطبيب بريمولت ان، والجرعة بشكل عام تكون 2 - 3 أقراص في اليوم. في بعض الحالات، قد تحتاجين لتناول بريمولت ان كل يوم، ولكل هذه ليست الحالة دائما.</p><p dir="RTL">استشيري طبيبك أو الصيدلي إذا لم تكوني متأكدة من عدد الأقراص التي ينبغي عليك تناولها، ومتى ينبغي تناولها ولكم من الوقت.</p><p dir="RTL">ابتلعي الأقراص كاملة مع شربة ماء.</p><p dir="RTL"><strong>إذا تناولت بريمولوت ن أكثر مما ينبغي</strong></p><p dir="RTL">من غير المرجح أن يتسبب تناول الكثير من الأقراص في أي مشاكل خطيرة إذا تناولت الكثير منهم، اتصلي بطبيبك الذي سيخبرك بما ينبغي عليك عمله</p><p dir="RTL"><strong>إذا نسيت تناول بريمولوت ن</strong></p><p dir="RTL">إذا نسيت تناول جرعة، انتظري حتى يحين موعد الجرعة التالية حسب وصف الطبيب. لا تتناولي الجرعة المنسية. إذا كنت قلقة، اتصلي بطبيبك أو الصيدلي.</p><p dir="RTL">إذا كان لديك المزيد من الأسئلة، اسألي طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، من الممكن أن يتسبب هذا الدواء في آثار جانبية، وإن لم تكن تصيب الجميع.</p><p dir="RTL"><strong>أسباب لإيقاف بريمولوت ن على الفور</strong></p><p dir="RTL">توقفي عن تناول بريمولوت ن واتصلي بطبيبك على الفور إذا حدث لك أي مما يلي:</p><ul dir="rtl"><li>صداع نصفى (شقيقة) لأول مرة</li><li>صداع سئ بشكل غير عادي ويحدث بعدد مرات أكثر من ذي قبل</li><li>تغيرات مفاجئة في البصر أو السمع أو الكلام</li><li>تغيرات مفاجئة في حاسة الشم أو التذوق أو اللمس</li><li>أعراض تكون جلطات دموية أو أعراض لالتهاب الأوردة مصحوبا بتكون جلطات دموية (التهاب الوريد الخثاري):</li><li>آلام غير عادية في ساقك (ساقيك)</li><li>تورم غير عادي في ذراعيك أو ساقيك</li><li>آلام حادة في صدرك أو ضيق مفاجئ في التنفس</li><li>آلام شديدة أو الشعور بثقل أو ضيق في صدرك</li><li>سعال بدون سبب واضح</li><li>أحد جانبيك يصبح فجأة ضعيف جدا أو به خدر</li></ul><p dir="RTL"><strong>ينبغي أيضا إيقاف بريمولوت ن على الفور إذا:</strong></p><ul dir="rtl"><li>أصبحت حاملا</li><li>أصبت باليرقان أو مشاكل أخرى في الكبد</li><li>أصبت بالحكة</li><li>وجد طبيبك أن ضغط دمك أصبح مرتفعا للغاية</li></ul><p dir="RTL"><strong>آثار جانبية عامة:</strong></p><p dir="RTL">فيما يلي يتم سرد الآثار الجانبية التي تم الإبلاغ عنها مع بريمولوت ن وفقا لتكرارية حدوثها.</p><p dir="RTL"><strong>آثار جانبية شائعة جدا </strong>(قد تصيب أكثر من 1 من كل 10 أشخاص)</p><ul dir="rtl"><li>نزيف مهبلي، بما في ذلك التبقيع</li><li>الدورات الشهرية تكون أقصر كثيرا من المعتاد ويقل تدفق الدم.</li></ul><p dir="RTL"><strong>آثار جانبية شائعة </strong>(قد تصيب حتى 1 من 10 أشخاص)</p><ul dir="rtl"><li>صداع</li><li>الشعور بالإعياء (الغثيان)</li><li>غياب الدورة الشهرية</li><li>تورم</li></ul><p dir="RTL"><strong>آثار جانبية غير شائعة </strong>(قد تصيب حتى 1 من كل &nbsp;100 شخص)</p><ul dir="rtl"><li>صداع نصفي</li></ul><p dir="RTL"><strong>آثار جانبية نادرة </strong>(قد تصيب حتى 1 من كل 1,000 شخص)</p><ul dir="rtl"><li>تفاعلات حساسية بما في ذلك الطفح الجلدي أو &laquo;الشرى&raquo;</li></ul><p dir="RTL"><strong>آثار جانبية نادرة جدا </strong>(قد تصيب حتى 1 من كل 10,000 شخص)</p><ul dir="rtl"><li>إضطرابات بصرية</li><li>صعوبة في التنفس</li></ul><p dir="RTL"><strong>آثار جانبية أخرى </strong>(تكرر غير معروف: حالات لا يمكن تقديرها من البيانات المتاحة)</p><ul dir="rtl"><li>تفاقم الاكتئاب</li><li>دوخة</li><li>ألم في البطن</li><li>يرقان</li><li>ركود صفراوي</li></ul><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا أصبت بأي أعراض جانبية، أخبر طبيبك أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة وغير مذكورة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">فاكس: 7662 &ndash; 205 &ndash; 11 &ndash; 966 +</p><p dir="RTL">مركز اتصال الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني: https://ade.sfda.gov.sa</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيداً عن نظر و متناول الأطفال.</p><p dir="RTL">يحفظ في العبوة الأصلية في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">لا تتناولي هذا الدواء بعد تاريخ انتهاء المفعول المذكور على كل من العلبة الخارجية وعلى كل شريط من شرائط الأقراص بعد كلمة تاريخ الإنتهاء &laquo;EXP&raquo;. يشير تاريخ انتهاء المفعول إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تتخلصي من أي أدوية عن طريق الصرف الصحي أو النفايات المنزلية. اسألي الصيدلي كيف تتخلص من الأدوية التي لم تعد تحتاج إليها. هذه الإجراءات سوف تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحتوي كل قرص على 5 مجم من المادة الفعالة نوريثيستيرون. المكونات الأخرى هي لاكتوز، نشا الذرة وستيرات المغنيسيوم (E572).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو بريمولوت ن ومحتويات العبوة</strong></p><p dir="RTL">أقراص بيضاء، بحز متصالب على جانب واحد مع رمز محفور &lsquo;AN&rsquo; داخل مضلع سداسي (مضلع مسدس الزوايا و الأضلاع) على الجانب الآخر.</p><p dir="RTL">تحتوي على 2&times;15 قرص في عبوة شرائط (بي. في. سي / ألومينيوم).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المصنع</strong></p><p dir="RTL">باير فايمر جي ام بي اتش اند كو. كي جي</p><p dir="RTL">99427 فايمر، ألمانيا.</p><p dir="RTL"><strong>التابع لـشركة </strong></p><p dir="RTL">باير ايه جي</p><p dir="RTL">1 طريق القيصر ويلهلم،</p><p dir="RTL">51373 ليفركوزن، ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في ديسمبر 2018.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Primolut N®
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 5 milligrams of norethisterone BP. Excipient with known effect
Lactose
For the full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.

White, uncoated tablets impressed with ‘AN’ in a regular hexagon on one side

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Metropathia &nbsp;haemorrhagica. Premenstrual &nbsp;syndrome.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Postponement of menstruation. Endometriosis. Menorrhagia. Dysmenorrhoea</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:47.25pt"><u>Posology</u></p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:0in; text-align:justify">Not intended for use in children.</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:19.9pt; text-align:justify"><em>Metropathia haemorrhagica (dysfunctional uterine bleeding): </em>1 tablet 3 times daily for 10 days. Bleeding is arrested usually within 1-3 days. A withdrawal bleeding resembling normal menstruation occurs within 2-4 days after discontinuing treatment. One tablet twice daily from the 19th to the 26th day of the two subsequent cycles should be given to prevent recurrence of the condition.</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:20.15pt; text-align:justify">To ensure treatment success, Primolut N must be taken for the full 10 days. Occasionally, slight bleeding may occur after the initial suspension of bleeding. Treatment should not be interrupted or suspended in these cases.</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:19.8pt; text-align:justify">If vaginal bleeding does not stop, despite correct tablet intake, an organic cause or an extra- genital factor (e.g. polyps, carcinoma of the cervix uteri or endometrium, myoma, residua of abortion, extra-uterine pregnancy, or coagulation disorders) must be considered so that other measures are then mostly required. This also applies to cases where after an initial suspension of bleeding, fairly heavy bleeding reoccurs during tablet intake.</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:19.65pt; text-align:justify"><em>Premenstrual syndrome (including premenstrual mastalgia): </em>Premenstrual symptoms such as headache, migraine, breast discomfort, water retention, tachycardia, and psychological disturbances may be relieved by the administration of 1-3 tablets daily from the 19th to the 26th day of the cycle. Treatment should be repeated for several cycles. When treatment is stopped, the patient may remain symptom-free for a number of months.</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:20.0pt; text-align:justify"><em>Postponement of menstruation: </em>In cases of too frequent menstrual bleeding, and in special circumstances (e.g. operations, travel, sports) the postponement of menstruation is possible. The dosage is 1 tablet of Primolut N three times daily, starting 3 days before the expected onset of menstruation and continuing for not longer than 10 to 14 days. A normal period should occur 2-3 days after the patient has stopped taking tablets. This method should be restricted to users who are not at risk of pregnancy during the treatment cycle.</p><p>&nbsp;</p><p style="margin-left:48.3pt; margin-right:18.4pt; text-align:justify"><em>Endometriosis (pseudo-pregnancy therapy): </em>Treatment should begin between the first and 5th day of the cycle with 1 of tablet Primolut N twice daily. In the event of spotting, the dose can be increased to 2 tablets twice daily. If bleeding ceases, dose reduction to the initial dose should be considered. Treatment is to be continued for at least 4 to 6 months. With uninterrupted daily intake, ovulation and menstruation do not usually occur.</p><p>&nbsp;</p><p style="margin-left:48.3pt; margin-right:18.7pt; text-align:justify"><em>Menorrhagia (hypermenorrhoea): </em>1 tablet 2-3 times a day from the 19th to the 26th day of the cycle (counting the first day of menstruation as day 1).</p><p>&nbsp;</p><p style="margin-left:48.3pt; margin-right:18.9pt; text-align:justify"><em>Dysmenorrhoea: </em>Functional or primary dysmenorrhoea is almost invariably relieved by the suppression of ovulation. 1 tablet three times daily for 20 days, starting on the fifth day of the cycle (the first day of menstruation counting as day 1). Treatment should be maintained for three to four cycles followed by treatment-free cycles. A further course of therapy may be employed if symptoms return.</p><p>&nbsp;</p><p style="margin-left:48.3pt; text-align:justify"><u>Method of administration</u></p><p>&nbsp;</p><p style="margin-left:48.3pt; margin-right:0in">Oral use. The tablets are to be swallowed whole with some liquid.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Primolut N should not be used in the presence of any of the conditions listed below. Should any of the conditions appear during the use of Primolut N, the use of the product should be stopped immediately.

1.	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
2.	Known or suspected pregnancy.
3.	Lactation.
4.	Previous idiopathic or current venous thromboembolism (deep vein thrombosis, pulmonary embolism).
5.	Active or recent arterial thromboembolic disease (e.g. angina, myocardial infarction).
6.	Presence or a history of prodromi of a thrombosis (e.g. transient ischaemic attack, angina pectoris).
7.	A high risk of venous or arterial thrombosis (see section 4.4)
8.	History of migraine with focal neurological symptoms.
9.	Diabetes mellitus with vascular involvement.
10.	Presence or history of severe hepatic disease as long as liver function values have not returned to normal.
11.	Previous or existing liver tumours (benign or malignant).
12.	Known, past or suspected sex hormone-dependent malignancies, including of the genital organs or breast cancer.
13.	History during pregnancy of idiopathic jaundice or severe pruritus.
14.	Undiagnosed genital bleeding.
15.	Untreated endometrial hyperplasia.

Primolut N is contraindicated for concomitant use with the medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir (see section 4.4 and 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:48.3pt"><u>Medical Examination</u></p><p style="margin-left:48.3pt; margin-right:18.65pt; text-align:justify">A complete personal and family medical history should be taken for each woman. Physical examination should be guided by this and by the contraindications (section 4.3) and warnings (section 4.4) for this product. The frequency and nature of these assessments should be based upon relevant guidelines which should be adapted to the individual woman and should include measurement of blood pressure, and if judged appropriate by the clinician, breast, abdominal and pelvic examination including cervical cytology.</p><p>&nbsp;</p><p style="margin-left:48.3pt">Therapy should be discontinued immediately if the following occur:</p><p style="margin-left:76.75pt; margin-right:18.8pt; text-indent:-21.35pt"><!--[if !supportLists]-->&sect;&nbsp;&nbsp; <!--[endif]-->New onset of migraine-type headaches or more frequent occurrence of unusually severe headaches</p><p>&nbsp;</p><p><!--[if !supportLists]-->&sect;&nbsp;&nbsp; <!--[endif]-->Sudden perceptual disorders (e.g. disturbances of vision or hearing)</p><p style="margin-right:20.15pt"><!--[if !supportLists]-->&sect;&nbsp;&nbsp; <!--[endif]-->First signs of thrombophlebitis or thromboembolic symptoms, feeling of pain and tightness in the chest</p><p><!--[if !supportLists]-->&sect;&nbsp;&nbsp; <!--[endif]-->Pending operations (six weeks beforehand), immobilisation (e.g. after accidents)</p><p><!--[if !supportLists]-->&sect;&nbsp;&nbsp; <!--[endif]-->Onset of jaundice or deterioration in liver function, anicteric hepatitis, general pruritus</p><p><!--[if !supportLists]-->&sect;&nbsp;&nbsp; <!--[endif]-->Significant increase in blood pressure</p><p><!--[if !supportLists]-->&sect;&nbsp;&nbsp; <!--[endif]-->Pregnancy.</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:19.75pt; text-align:justify">If any of the conditions/risk factors mentioned below is present or deteriorates while using Primolut N, an individual risk-benefit analysis should be done before Primolut N is started or continued.</p><p>&nbsp;</p><p style="margin-left:68.6pt; text-align:justify; text-indent:-18.95pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;&nbsp; Circulatory disorders</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:20.15pt; text-align:justify">It has been concluded from epidemiological surveys that the use of oral oestrogen/progestogen containing ovulation inhibitors is associated by an increased incidence of thromboembolic diseases. Therefore, one should keep the possibility of an increased thromboembolic risk in mind, particularly where there is a history of thromboembolic diseases.</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:20.05pt; text-align:justify">A patient who develops symptoms suggestive of thromboembolic complications should stop treatment immediately. The need for treatment should be reassessed before continuing therapy.</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:0in; text-align:justify">Generally recognised risk factors for venous thromboembolism (VTE) include:</p><p style="margin-left:58.3pt; text-align:justify; text-indent:-11.05pt"><!--[if !supportLists]-->1.&nbsp; <!--[endif]-->Positive personal or family history (VTE in a sibling or a parent at a relatively early age)</p><p style="margin-left:58.3pt; text-align:justify; text-indent:-11.05pt"><!--[if !supportLists]-->2.&nbsp; <!--[endif]-->Age</p><p style="margin-left:58.3pt; text-align:justify; text-indent:-11.05pt"><!--[if !supportLists]-->3.&nbsp; <!--[endif]-->Obesity</p><p style="margin-left:58.3pt; text-align:justify; text-indent:-11.05pt"><!--[if !supportLists]-->4.&nbsp; <!--[endif]-->Systemic lupus erythematous (SLE)</p><p style="margin-left:58.3pt; text-align:justify; text-indent:-11.05pt"><!--[if !supportLists]-->5.&nbsp; <!--[endif]-->Prolonged immobilisation</p><p style="margin-left:58.3pt; text-align:justify; text-indent:-11.05pt"><!--[if !supportLists]-->6.&nbsp; <!--[endif]-->Major surgery</p><p style="margin-left:58.3pt; text-align:justify; text-indent:-11.05pt"><!--[if !supportLists]-->7.&nbsp; <!--[endif]-->Major trauma.</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:19.95pt; text-align:justify">Patients with a history of VTE or known thrombophilic states have an increased risk of VTE. The treatment with steroid hormone may add to this risk. Personal or strong family history of thromboembolism or recurrent spontaneous abortion should be investigated in order to exclude a thromboembolic predisposition. Until a thorough evaluation of thrombophilic factors has been made or anticoagulant treatment initiated, use of progestogens in these patients should be viewed as contraindicated. Where a patient is already taking anticoagulants, the risk and benefits of progestogen therapy should be carefully considered.</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:19.8pt; text-align:justify">The risk of VTE may be temporarily increased with prolonged immobilisation, major trauma or major surgery. As in all post-operative patients, scrupulous attention should be given to prophylactic measures to prevent VTE. Where prolonged immobilisation is likely to follow elective surgery, particularly abdominal or orthopaedic surgery to the lower limbs, consideration should be given to stopping progestogen therapy 4-6 weeks pre-operatively. Treatment should not be restarted until the patient is fully remobilised.</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:20.2pt; text-align:justify">There is no consensus about the possible role of varicose veins and superficial thrombophlebitis in venous thromboembolism.</p><p>&nbsp;</p><p style="margin-left:68.6pt; text-align:justify; text-indent:-18.95pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;&nbsp; Known Hyperlipidaemias</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:20.15pt; text-align:justify">Women with hypertriglyceridemia, or a family history thereof, may be at increased risk of pancreatitis when using COCs.</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:20.15pt; text-align:justify">Women with hyperlipiaedmia are at increased risk of arterial disease (see section 4.4 &ldquo;Circulatory disorders&rdquo;). However, routine screening of women on COCs is not appropriate.</p><p>&nbsp;</p><p style="margin-left:68.6pt; text-align:justify; text-indent:-18.95pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;&nbsp; Tumours</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:19.8pt; text-align:justify">In rare cases, benign liver tumours, and even more rarely, malignant liver tumours have been reported in users of hormonal substances such as the one contained in Primolut N. In isolated cases, these tumours have led to life-threatening intra-abdominal haemorrhages. If severe upper abdominal complaints, liver enlargement or signs of intra-abdominal haemorrhage occur,</p><p>&nbsp;</p><p style="margin-left:48.3pt; margin-right:19.05pt; text-align:justify">a liver tumour should be included in the differential diagnosis and, if necessary, the preparation should be withdrawn.</p><p>&nbsp;</p><p style="margin-left:76.75pt; text-align:justify; text-indent:-26.05pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Other</p><p>&nbsp;</p><p style="margin-left:48.3pt; margin-right:19.25pt; text-align:justify">Primolut-N can influence carbohydrate metabolism. Parameters of carbohydrate metabolism should be examined carefully in all diabetics before and regularly during treatment.</p><p>&nbsp;</p><p style="margin-left:48.3pt; margin-right:18.7pt; text-align:justify">Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should minimise exposure to the sun or ultraviolet radiation when taking Primolut N.</p><p>&nbsp;</p><p style="margin-left:48.3pt; margin-right:19.0pt; text-align:justify">Patients who have a history of depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree.</p><p>&nbsp;</p><p style="margin-left:48.3pt; margin-right:19.1pt; text-align:justify">Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p><p style="margin-left:48.3pt; margin-right:18.7pt; text-align:justify">Any patient who develops an acute impairment of vision, proptosis, diplopia or migraine headache should be carefully evaluated ophthalmologically to exclude papilloedema or retinal lesions before continuing medication.</p><p>&nbsp;</p><p style="margin-left:48.3pt; margin-right:19.05pt; text-align:justify">Progestogens may cause fluid retention. Special care should be taken when prescribing norethisterone in patients with conditions which might be aggravated by this factor:</p><p style="margin-left:76.75pt; text-indent:-21.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Epilepsy</p><p style="margin-left:76.75pt; text-indent:-21.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Migraine</p><p style="margin-left:76.75pt; text-indent:-21.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Asthma</p><p style="margin-left:76.75pt; text-indent:-21.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Cardiac dysfunction</p><p style="margin-left:76.75pt; text-indent:-21.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Renal dysfunction.</p><p>&nbsp;</p><p style="margin-left:48.3pt; margin-right:18.95pt; text-align:justify">If menstrual bleeding should fail to follow a course of Primolut N, or if the patient wishes to postpone menstruation in special circumstances, the possibility of pregnancy must be excluded before a further course is given.</p><p>&nbsp;</p><p>Additional warnings based on the partial metabolisation of norethisterone to ethinylestradiol</p><p><strong>&nbsp;</strong></p><p style="margin-left:48.3pt; margin-right:18.75pt; text-align:justify">After oral administration, norethisterone is partly metabolised to ethinylestradiol resulting in an equivalent dose of about 4-6 micrograms ethinylestradiol per 1 milligram of orally administered norethisterone or norethisterone acetate (see section 5.2)</p><p>&nbsp;</p><p style="margin-left:48.3pt; margin-right:18.9pt; text-align:justify">Due to the partial conversion of norethisterone to ethinylestradiol, administration of Primolut N is expected to result in similar pharmacological effects as seen with COCs. Therefore, the following general warnings associated with the use of COCs should also be considered:</p><p>&nbsp;</p><p style="margin-left:69.7pt; text-align:justify; text-indent:-19.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Circulatory disorders (thromboembolic events)</p><p>&nbsp;</p><p style="margin-left:48.3pt; text-align:justify"><em><u>Venous thromboembolic events (VTE)</u></em></p><p style="margin-left:48.3pt; margin-right:18.65pt; text-align:justify">Epidemiological studies have shown that the incidence of venous thromboembolism (VTE) in users of oral contraceptives with low oestrogen content (&lt;50 &micro;g ethinylestradiol) ranges from about 20 to 40 cases per 100,000 women-years, but this risk estimate varies according to the progestogen. This compares with 5 to 10 cases per 100,000 women-years for non-users. The use of any combined oral contraceptive carries an increased risk of VTE compared with no use. This increased risk is less than the risk of VTE associated with pregnancy, which is estimated as 60 cases per 100,000 pregnancies. The excess risk of VTE is highest during the first year a woman initially starts using a COC or when she restarts COC use after a pill-free interval of at least a month.</p><p>&nbsp;</p><p style="margin-left:48.3pt; text-align:justify">VTE may be life-threatening or may have a fatal outcome (in 1-2 % of the cases).</p><p>&nbsp;</p><p style="margin-left:48.3pt; margin-right:19.15pt; text-align:justify">VTE manifesting as deep venous thrombosis and/or pulmonary embolism, may occur during the use of all COCs.</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:0in">Extremely rarely, thrombosis has been reported to occur in other blood vessels, e.g. hepatic, mesenteric, renal, cerebral or retinal veins and arteries, in COC users.</p><p>&nbsp;</p><p style="margin-left:47.25pt">Common signs/symptoms of VTE include:</p><p style="margin-left:68.6pt; text-indent:-18.95pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Severe pain in the calf of one leg; swelling of the lower leg</p><p style="margin-left:68.6pt; text-indent:-18.95pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Sudden breathlessness, chest pain.</p><p>&nbsp;</p><p style="margin-left:47.25pt"><em><u>Arterial thromboembolic related conditions</u></em></p><p style="margin-left:47.25pt; margin-right:20.15pt">The use of a combined oral contraceptive may also increase the risk of conditions such as stroke and myocardial infarction which are secondary to arterial thromboembolic events.</p><p>&nbsp;</p><p style="margin-left:47.25pt">Common signs/symptoms associated with arterial thromboembolism include:</p><p style="margin-left:68.6pt; text-indent:-18.95pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden severe pain in the chest, whether or not reaching to the left arm;</p><p style="margin-left:68.6pt; text-indent:-18.95pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden coughing for no apparent reason</p><p style="margin-left:68.6pt; margin-right:19.8pt; text-indent:-18.95pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->any unusual severe, prolonged headache, especially if it occurs for the first time or gets progressively worse, or is associated with any of the following symptoms:</p><p style="margin-left:89.85pt; text-indent:-14.15pt"><!--[if !supportLists]-->o&nbsp;&nbsp; <!--[endif]-->sudden partial or complete loss of vision or diplopia;</p><p style="margin-left:89.85pt; text-indent:-14.15pt"><!--[if !supportLists]-->o&nbsp;&nbsp; <!--[endif]-->aphasia;</p><p style="margin-left:89.85pt; text-indent:-14.15pt"><!--[if !supportLists]-->o&nbsp;&nbsp; <!--[endif]-->vertigo;</p><p style="margin-left:89.85pt; text-indent:-14.15pt"><!--[if !supportLists]-->o&nbsp;&nbsp; <!--[endif]-->collapse with or without focal epilepsy;</p><p style="margin-left:89.85pt; margin-right:19.8pt; text-indent:-14.15pt"><!--[if !supportLists]-->o&nbsp;&nbsp; <!--[endif]-->weakness or very marked numbness suddenly affecting one side or one part of the body.</p><p>&nbsp;</p><p style="margin-left:47.25pt">Risk Factors for Thromboembolic Events:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Age</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Obesity (body mass index over 30 kg/m2)</p><p style="margin-right:19.85pt; text-align:justify"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->A positive family history (i.e. venous or arterial thromboembolism ever in a sibling or parent at a relatively early age). If a hereditary predisposition is known or suspected, the woman should be referred to a specialist for advice before deciding about any COC use</p><p style="margin-left:75.7pt; margin-right:19.95pt; text-align:justify"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Prolonged immobilisation, major surgery, any surgery to the legs, or major trauma. In these situations it is advisable to discontinue COC use (in the case of elective surgery at least four weeks in advance) and not to resume until two weeks after complete remobilisation</p><p style="margin-left:75.7pt; margin-right:19.9pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Smoking (with heavier smoking and increasing age the risk further increases, especially in women over 35 years of age)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Dyslipoproteinaemia</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Hypertension</p><p style="margin-left:75.7pt; margin-right:20.1pt; text-align:justify"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Migraine (An increase in frequency or severity of migraine during COC use may be prodromal of a cerebrovascular event and therefore a reason for immediate discontinuation of the COC).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Valvular heart disease</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Atrial fibrillation</p><p>&nbsp;</p><p style="margin-left:47.25pt"><em><u>Other factors affecting circulatory events</u></em></p><p><em>&nbsp;</em></p><p style="margin-left:47.25pt; margin-right:0in">Other medical conditions which have been associated with adverse circulatory events include:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Diabetes mellitus</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Systemic lupus erythematosus (SLE)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Haemolytic uremic syndrome</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Chronic inflammatory bowel disease (Crohn&rsquo;s disease/Ulcerative colitis)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Sickle cell disease.</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:19.75pt">Biochemical factors that may be indicative of hereditary or acquired predisposition for venous or arterial thrombosis include:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Activated Protein C (APC) resistance</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Hyperhomocysteinaemia</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Antithrombin-III deficiency</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Protein C deficiency</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Protein S deficiency</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant).</p><p>&nbsp;</p><p style="margin-left:48.3pt; margin-right:18.95pt; text-align:justify">When considering risk/benefit, the physician should take into account that adequate treatment of a condition may reduce the associated risk of thrombosis and that the risk associated with pregnancy is higher than that associated with COC use (&lt;0.05 mg ethinylestradiol).</p><p>&nbsp;</p><p style="margin-left:69.7pt; text-indent:-19.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Tumours</p><p>&nbsp;</p><p style="margin-left:48.3pt"><em><u>Cervical Cancer</u></em></p><p style="margin-left:48.3pt; margin-right:18.7pt; text-align:justify">The most important risk factor for cervical cancer is persistent HPV infection. Some epidemiological studies have indicated that long-term use of COCs may further contribute to this increased risk but there continues to be controversy about the extent to which this finding is attributable to confounding effects, e.g., cervical screening and sexual behaviour including use of barrier contraceptives.</p><p>&nbsp;</p><p style="margin-left:48.3pt"><em><u>Breast Cancer</u></em></p><p style="margin-left:48.3pt; margin-right:18.7pt; text-align:justify">A meta-analysis from 54 epidemiological studies reported that there is a slightly increased relative risk (RR = 1.24) of having breast cancer diagnosed in women who are currently using COCs. The excess risk gradually disappears during the course of the 10 years after cessation of COC use. Because breast cancer is rare in women under 40 years of age, the excess number of breast cancer diagnoses in current and recent COC users is small in relation to the overall risk of breast cancer. These studies do not provide evidence for causation. The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in COC users, the biological effects of COCs or a combination of both. The breast cancers diagnosed in ever-users tend to be less advanced clinically than the cancers diagnosed in never-users.</p><p>&nbsp;</p><p style="margin-left:48.3pt">Malignancies may be life-threatening or may have a fatal outcome.</p><p>&nbsp;</p><p style="margin-left:69.7pt; text-indent:-19.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Other</p><p>&nbsp;</p><p style="margin-left:48.3pt"><em><u>Blood pressure</u></em></p><p style="margin-left:48.3pt; margin-right:18.65pt; text-align:justify">Although small increases in blood pressure have been reported in many women taking COCs, clinically relevant increases are rare. However, if a sustained clinically significant hypertension develops during the use of a COC then it is prudent for the physician to withdraw the COC and treat the hypertension. Where considered appropriate, COC use may be resumed if normotensive values can be achieved with antihypertensive therapy.</p><p>&nbsp;</p><p style="margin-left:48.3pt"><em><u>Conditions which deteriorate in pregnancy or during previous COC use</u></em></p><p style="margin-left:48.3pt; margin-right:20.15pt">The following conditions have been reported to occur or deteriorate with both pregnancy and COC use, but the evidence of an association with COC use is inconclusive:</p><p style="margin-left:76.75pt; text-indent:-21.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->jaundice and/or pruritus related to cholestasis</p><p style="margin-left:76.75pt; text-indent:-21.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->gallstone formation</p><p style="margin-left:76.75pt; text-indent:-21.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->porphyria</p><p style="margin-left:76.75pt; text-indent:-21.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->systemic lupus erythematosus (SLE)</p><p style="margin-left:76.75pt; text-indent:-21.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->haemolytic uremic syndrome</p><p style="margin-left:76.75pt; text-indent:-21.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Sydenham&rsquo;s chorea</p><p style="margin-left:76.75pt; text-indent:-21.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->herpes gestationis</p><p style="margin-left:76.75pt; text-indent:-21.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->otosclerosis-related hearing loss.</p><p>&nbsp;</p><p style="margin-left:48.3pt; margin-right:20.15pt">In women with hereditary angioedema exogenous estrogens may induce or exacerbate symptoms of angioedema.</p><p>&nbsp;</p><p style="margin-left:48.3pt; margin-right:18.85pt; text-align:justify">Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal. Recurrence of cholestatic jaundice which occurred first during pregnancy or previous use of sex steroids necessitates the discontinuation of COCs.</p><p style="margin-left:48.3pt; margin-right:93.5pt">Crohn&rsquo;s disease and ulcerative colitis have been associated with COC use. <u>ALT elevations</u></p><p style="margin-left:48.3pt">During clinical trials with patients treated for hepatitis C virus infections (HCV) with the</p><p style="margin-left:48.3pt; margin-right:42.95pt">medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin, transaminase (ALT) elevations higher than 5 times the upper limit of</p><p style="margin-left:48.3pt; text-align:justify">normal (ULN) occurred significantly more frequent in women using ethinylestradiol-containing</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:19.45pt; text-align:justify">medications such as combined hormonal contraceptives (CHCs). As norethisterone is partly metabolized into ethinylestradiol, this warning applies to women using norethisterone (see sections 4.3 and 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:47.25pt; margin-right:19.6pt; text-align:justify">Note: the prescribing information of concomitant medications should be consulted to identify interactions.</p><p>&nbsp;</p><p><u>Effects of other medicinal products on Primolut N</u></p><p><strong><em>&nbsp;</em></strong></p><p style="margin-left:47.25pt; margin-right:19.75pt; text-align:justify">Interactions can occur with drugs that induce microsomal enzymes, which can result in increased clearance of sex hormones and which may lead to changes in the uterine bleeding profile and/or reduction of the therapeutic effect.</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:20.15pt; text-align:justify">Enzyme induction can already be observed after a few days of treatment. Maximal enzyme induction is generally seen within a few weeks. After the cessation of drug therapy enzyme induction may be sustained for about 4 weeks.</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:19.8pt; text-align:justify"><em>Substances increasing the clearance of sex hormones (diminished efficacy by enzyme- induction), e.g.:</em></p><p><em>&nbsp;</em></p><p style="margin-left:47.25pt; margin-right:20.05pt; text-align:justify">Phenytoin, barbiturates, bosentan, primidone, carbamazepine, rifampicin and HIV medication ritonavir, nevirapine and efavirenz, and possibly also oxcarbazepine, topiramate, felbamate, griseofulvin and products containing St. John&rsquo;s wort (Hypericum perforatum).</p><p>&nbsp;</p><p style="margin-left:47.25pt; text-align:justify"><em>Substances with variable effects on the clearance of sex hormones, e.g.:</em></p><p><em>&nbsp;</em></p><p style="margin-left:47.25pt; margin-right:19.8pt; text-align:justify">When co-administered with sex hormones, many HIV/HCV protease inhibitors and non- nucleoside reverse transcriptase inhibitors can increase or decrease plasma concentrations of estrogen or progestin. These changes may be clinically relevant in some cases.</p><p>&nbsp;</p><p style="margin-left:47.25pt; text-align:justify"><em>Substances decreasing the clearance of sex hormones (enzyme inhibitors):</em></p><p style="margin-left:47.25pt; text-align:justify">The clinical relevance of potential interactions with enzyme inhibitors remains unknown.</p><p style="margin-left:47.25pt; margin-right:20.1pt; text-align:justify">Strong and moderate CYP3A4 inhibitors such as azole antifungals (e.g. itraconazole, voriconazole, fluconazole), verapamil, macrolides (e.g. clarithromycin, erythromycin), diltiazem and grapefruit juice can increase plasma concentrations of the estrogen or the progestin or both.</p><p style="margin-left:47.25pt; margin-right:19.9pt; text-align:justify">Etoricoxib doses of 60 to 120 mg/day have been shown to increase plasma concentrations of ethinylestradiol 1.4 to 1.6-fold, respectively when taken concomitantly with a combined hormonal medicinal product containing 0.035 mg ethinylestradiol.</p><p>&nbsp;</p><p><u>Effects of Primolut N on other medicinal products</u></p><p><strong><em>&nbsp;</em></strong></p><p style="margin-left:47.25pt; margin-right:0in">Progestogens may interfere with the metabolism of other drugs. Accordingly, plasma and tissue concentrations may either increase (e.g. ciclosporin) or decrease (e.g. lamotrigine).</p><p style="margin-left:47.25pt; margin-right:20.15pt">Clinical data suggest that ethinylestradiol inhibits the clearance of CYP1A2 substrates, leading to a weak (e.g. theophylline) or moderate (e.g. tizanidine) increase in plasma concentration.</p><p>&nbsp;</p><p><u>Pharmacodynamic interactions</u></p><p><strong><em>&nbsp;</em></strong></p><p style="margin-left:47.25pt; margin-right:19.8pt; text-align:justify">Concomitant use with the medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin may increase the risk of ALT elevations (see sections 4.3 and 4.4). Primolut N can be restarted 2 weeks following completion of treatment with this combination drug regimen.</p><p>&nbsp;</p><p><u>Other forms of interaction</u></p><p><strong><em>&nbsp;</em></strong></p><p style="margin-left:47.25pt; margin-right:20.15pt">The use of progestogens may influence the results of certain laboratory tests (e.g. tests for hepatic function, thyroid function and coagulation).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:48.3pt; text-align:justify"><u>Pregnancy</u></p><p style="margin-left:48.3pt; text-align:justify">The administration of Primolut N during pregnancy is contraindicated.</p><p>&nbsp;</p><p style="margin-left:48.3pt; margin-right:0in; text-align:justify"><u>Breast-feeding</u></p><p style="margin-left:48.3pt; text-align:justify">Primolut N can pass into breast milk and therefore should be avoided during lactation.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:48.3pt; text-align:justify">None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:48.3pt; margin-right:18.95pt; text-align:justify">Undesirable effects are more common during the first months after start of intake of Primolut preparations, and subside with duration of treatment. The frequencies are based on reporting rates from postmarketing experience and literature.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:black; height:11.45pt; vertical-align:top; width:73.8pt"><p style="margin-left:20.25pt">System</p></td><td style="height:11.45pt; vertical-align:top; width:70.95pt"><p style="margin-left:7.1pt; margin-right:6.55pt; text-align:center">Very</p></td><td style="height:11.45pt; vertical-align:top; width:77.9pt"><p style="margin-left:18.55pt">Common</p></td><td style="height:11.45pt; vertical-align:top; width:63.85pt"><p style="margin-left:6.2pt">Uncommon</p></td><td style="height:11.45pt; vertical-align:top; width:56.7pt"><p style="margin-left:6.0pt; margin-right:5.65pt; text-align:center">Rare</p></td><td style="height:11.45pt; vertical-align:top; width:70.95pt"><p style="margin-left:14.9pt">Very rare</p></td><td style="height:11.45pt; vertical-align:top; width:63.75pt"><p style="margin-left:8.4pt">Frequency</p></td></tr><tr><td style="height:34.55pt; vertical-align:top; width:73.8pt"><p style="margin-left:16.05pt; text-indent:-7.0pt">Organ Class (MeDRA)</p></td><td style="height:34.55pt; vertical-align:top; width:70.95pt"><p style="margin-left:16.05pt">common</p><p>&nbsp;</p><p style="margin-left:18.2pt">(&sup3; 1/10)</p></td><td style="height:34.55pt; vertical-align:top; width:77.9pt"><p>&nbsp;</p><p style="margin-left:19.8pt; margin-right:19.25pt; text-align:center">(&sup3; 1/100</p><p style="margin-left:19.7pt; margin-right:19.25pt; text-align:center">to</p></td><td style="height:34.55pt; vertical-align:top; width:63.85pt"><p>&nbsp;</p><p style="margin-left:5.15pt; margin-right:4.85pt; text-align:center">(&sup3; 1/1,000</p><p style="margin-left:5.2pt; margin-right:4.85pt; text-align:center">to</p></td><td style="height:34.55pt; vertical-align:top; width:56.7pt"><p>&nbsp;</p><p style="margin-left:8.95pt; margin-right:0in; text-indent:14.85pt">(&sup3; 1/10,000</p></td><td style="height:34.55pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p><p style="margin-left:8.3pt">(&lt; 1/10,000)</p></td><td style="height:34.55pt; vertical-align:top; width:63.75pt"><p>&nbsp;</p><p style="margin-left:5.75pt">(not known)</p></td></tr><tr><td style="height:14.35pt; vertical-align:top; width:73.8pt"><p>&nbsp;</p></td><td style="height:14.35pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:14.35pt; vertical-align:top; width:77.9pt"><p style="margin-left:23.35pt; margin-right:0in">&lt; 1/10)</p></td><td style="height:14.35pt; vertical-align:top; width:63.85pt"><p style="margin-left:13.5pt; margin-right:0in">&lt; 1/100)</p></td><td style="height:14.35pt; vertical-align:top; width:56.7pt"><p style="margin-left:6.0pt; margin-right:5.5pt; text-align:center">to</p></td><td style="height:14.35pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:14.35pt; vertical-align:top; width:63.75pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:22.3pt; vertical-align:top; width:73.8pt"><p>&nbsp;</p></td><td style="height:22.3pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:22.3pt; vertical-align:top; width:77.9pt"><p>&nbsp;</p></td><td style="height:22.3pt; vertical-align:top; width:63.85pt"><p>&nbsp;</p></td><td style="height:22.3pt; vertical-align:top; width:56.7pt"><p style="margin-left:6.0pt; margin-right:5.65pt; text-align:center">&lt; 1/1000)</p></td><td style="height:22.3pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:22.3pt; vertical-align:top; width:63.75pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:45.2pt; vertical-align:top; width:73.8pt"><p style="margin-left:5.35pt; margin-right:1.65pt">Immune system disorders</p></td><td style="height:45.2pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:45.2pt; vertical-align:top; width:77.9pt"><p>&nbsp;</p></td><td style="height:45.2pt; vertical-align:top; width:63.85pt"><p>&nbsp;</p></td><td style="height:45.2pt; vertical-align:top; width:56.7pt"><p style="margin-left:5.35pt">Hyper- sensitivity reactions</p></td><td style="height:45.2pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:45.2pt; vertical-align:top; width:63.75pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:45.2pt; vertical-align:top; width:73.8pt"><p style="margin-left:5.35pt; margin-right:1.65pt">Nervous system disorders</p></td><td style="height:45.2pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:45.2pt; vertical-align:top; width:77.9pt"><p style="margin-left:5.35pt">Headache</p></td><td style="height:45.2pt; vertical-align:top; width:63.85pt"><p style="margin-left:5.35pt">Migraine</p></td><td style="height:45.2pt; vertical-align:top; width:56.7pt"><p>&nbsp;</p></td><td style="height:45.2pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:45.2pt; vertical-align:top; width:63.75pt"><p style="margin-left:5.3pt">Dizziness</p></td></tr><tr><td style="border-color:black; height:33.8pt; vertical-align:top; width:73.8pt"><p style="margin-left:5.35pt">Psychiatric disorders</p></td><td style="height:33.8pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:33.8pt; vertical-align:top; width:77.9pt"><p>&nbsp;</p></td><td style="height:33.8pt; vertical-align:top; width:63.85pt"><p>&nbsp;</p></td><td style="height:33.8pt; vertical-align:top; width:56.7pt"><p>&nbsp;</p></td><td style="height:33.8pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:33.8pt; vertical-align:top; width:63.75pt"><p style="margin-left:5.3pt; margin-right:6.9pt">Depression aggravated</p></td></tr><tr><td style="border-color:black; height:33.8pt; vertical-align:top; width:73.8pt"><p style="margin-left:5.35pt">Eye disorders</p></td><td style="height:33.8pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:33.8pt; vertical-align:top; width:77.9pt"><p>&nbsp;</p></td><td style="height:33.8pt; vertical-align:top; width:63.85pt"><p>&nbsp;</p></td><td style="height:33.8pt; vertical-align:top; width:56.7pt"><p>&nbsp;</p></td><td style="height:33.8pt; vertical-align:top; width:70.95pt"><p style="margin-left:5.3pt">Visual disturbances</p></td><td style="height:33.8pt; vertical-align:top; width:63.75pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:56.6pt; vertical-align:top; width:73.8pt"><p style="margin-left:5.35pt">Respiratory, thoracic and mediastinal disorders</p></td><td style="height:56.6pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:56.6pt; vertical-align:top; width:77.9pt"><p>&nbsp;</p></td><td style="height:56.6pt; vertical-align:top; width:63.85pt"><p>&nbsp;</p></td><td style="height:56.6pt; vertical-align:top; width:56.7pt"><p>&nbsp;</p></td><td style="height:56.6pt; vertical-align:top; width:70.95pt"><p style="margin-left:5.3pt">Dyspnoea</p></td><td style="height:56.6pt; vertical-align:top; width:63.75pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:45.2pt; vertical-align:top; width:73.8pt"><p style="margin-left:5.35pt">Gastro- intestinal disorders</p></td><td style="height:45.2pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:45.2pt; vertical-align:top; width:77.9pt"><p style="margin-left:5.35pt">Nausea</p></td><td style="height:45.2pt; vertical-align:top; width:63.85pt"><p>&nbsp;</p></td><td style="height:45.2pt; vertical-align:top; width:56.7pt"><p>&nbsp;</p></td><td style="height:45.2pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:45.2pt; vertical-align:top; width:63.75pt"><p style="margin-left:5.3pt">Abdominal pain</p></td></tr><tr><td style="border-color:black; height:44.85pt; vertical-align:top; width:73.8pt"><p style="margin-left:5.35pt">Hepato-biliary disorders</p></td><td style="height:44.85pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:44.85pt; vertical-align:top; width:77.9pt"><p>&nbsp;</p></td><td style="height:44.85pt; vertical-align:top; width:63.85pt"><p>&nbsp;</p></td><td style="height:44.85pt; vertical-align:top; width:56.7pt"><p>&nbsp;</p></td><td style="height:44.85pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:44.85pt; vertical-align:top; width:63.75pt"><p style="margin-left:5.3pt">Cholestasis</p><p>&nbsp;</p><p style="margin-left:5.3pt">Jaundice</p></td></tr><tr><td style="border-color:black; height:56.6pt; vertical-align:top; width:73.8pt"><p style="margin-left:5.35pt; margin-right:1.65pt">Skin and subcutaneous tissue disorders</p></td><td style="height:56.6pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:56.6pt; vertical-align:top; width:77.9pt"><p>&nbsp;</p></td><td style="height:56.6pt; vertical-align:top; width:63.85pt"><p>&nbsp;</p></td><td style="height:56.6pt; vertical-align:top; width:56.7pt"><p style="margin-left:5.35pt">Urticaria Rash</p></td><td style="height:56.6pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:56.6pt; vertical-align:top; width:63.75pt"><p>&nbsp;</p></td></tr><tr><td style="height:11.2pt; vertical-align:top; width:73.8pt"><p style="margin-left:5.35pt">Reproductive</p></td><td style="height:11.2pt; vertical-align:top; width:70.95pt"><p style="margin-left:5.35pt">Uterine/</p></td><td style="height:11.2pt; vertical-align:top; width:77.9pt"><p style="margin-left:5.35pt">Amenorrhoea*</p></td><td rowspan="4" style="height:11.2pt; vertical-align:top; width:63.85pt"><p>&nbsp;</p></td><td rowspan="4" style="height:11.2pt; vertical-align:top; width:56.7pt"><p>&nbsp;</p></td><td rowspan="4" style="height:11.2pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td rowspan="4" style="height:11.2pt; vertical-align:top; width:63.75pt"><p>&nbsp;</p></td></tr><tr><td style="height:10.9pt; vertical-align:top; width:73.8pt"><p style="margin-left:5.35pt">system and</p></td><td style="height:10.9pt; vertical-align:top; width:70.95pt"><p style="margin-left:5.35pt">Vaginal</p></td><td style="height:10.9pt; vertical-align:top; width:77.9pt"><p>&nbsp;</p></td></tr><tr><td style="height:10.9pt; vertical-align:top; width:73.8pt"><p style="margin-left:5.35pt">breast</p></td><td style="height:10.9pt; vertical-align:top; width:70.95pt"><p style="margin-left:5.35pt">bleeding</p></td><td style="height:10.9pt; vertical-align:top; width:77.9pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:29.05pt; vertical-align:top; width:73.8pt"><p style="margin-left:5.35pt">disorders</p></td><td style="height:29.05pt; vertical-align:top; width:70.95pt"><p style="margin-left:5.35pt">including</p></td><td style="height:29.05pt; vertical-align:top; width:77.9pt"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:black; height:11.45pt; vertical-align:top; width:73.8pt"><p style="margin-left:20.25pt">System</p></td><td style="height:11.45pt; vertical-align:top; width:70.95pt"><p style="margin-left:7.1pt; margin-right:6.55pt; text-align:center">Very</p></td><td style="height:11.45pt; vertical-align:top; width:77.9pt"><p style="margin-left:18.55pt">Common</p></td><td style="height:11.45pt; vertical-align:top; width:63.85pt"><p style="margin-left:5.3pt; margin-right:4.85pt; text-align:center">Uncommon</p></td><td style="height:11.45pt; vertical-align:top; width:56.7pt"><p style="margin-left:6.0pt; margin-right:5.65pt; text-align:center">Rare</p></td><td style="height:11.45pt; vertical-align:top; width:70.95pt"><p style="margin-left:7.1pt; margin-right:7.05pt; text-align:center">Very rare</p></td><td style="height:11.45pt; vertical-align:top; width:63.75pt"><p style="margin-right:7.65pt; text-align:right">Frequency</p></td></tr><tr><td style="height:34.6pt; vertical-align:top; width:73.8pt"><p style="margin-left:16.05pt; text-indent:-7.0pt">Organ Class (MeDRA)</p></td><td style="height:34.6pt; vertical-align:top; width:70.95pt"><p style="margin-left:16.05pt">common</p><p>&nbsp;</p><p style="margin-left:18.2pt">(&sup3; 1/10)</p></td><td style="height:34.6pt; vertical-align:top; width:77.9pt"><p>&nbsp;</p><p style="margin-left:19.8pt; margin-right:19.25pt; text-align:center">(&sup3; 1/100</p><p style="margin-left:19.7pt; margin-right:19.25pt; text-align:center">to</p></td><td style="height:34.6pt; vertical-align:top; width:63.85pt"><p>&nbsp;</p><p style="margin-left:5.15pt; margin-right:4.85pt; text-align:center">(&sup3; 1/1,000</p><p style="margin-left:5.2pt; margin-right:4.85pt; text-align:center">to</p></td><td style="height:34.6pt; vertical-align:top; width:56.7pt"><p>&nbsp;</p><p style="margin-left:8.95pt; text-indent:14.85pt">(&sup3; 1/10,000</p></td><td style="height:34.6pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p><p style="margin-left:7.1pt; margin-right:7.05pt; text-align:center">(&lt; 1/10,000)</p></td><td style="height:34.6pt; vertical-align:top; width:63.75pt"><p>&nbsp;</p><p style="margin-right:5.25pt; text-align:right">(not known)</p></td></tr><tr><td style="height:14.35pt; vertical-align:top; width:73.8pt"><p>&nbsp;</p></td><td style="height:14.35pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:14.35pt; vertical-align:top; width:77.9pt"><p style="margin-left:23.35pt; margin-right:0in">&lt; 1/10)</p></td><td style="height:14.35pt; vertical-align:top; width:63.85pt"><p style="margin-left:5.25pt; margin-right:4.85pt; text-align:center">&lt; 1/100)</p></td><td style="height:14.35pt; vertical-align:top; width:56.7pt"><p style="margin-left:6.0pt; margin-right:5.5pt; text-align:center">to</p></td><td style="height:14.35pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:14.35pt; vertical-align:top; width:63.75pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:22.3pt; vertical-align:top; width:73.8pt"><p>&nbsp;</p></td><td style="height:22.3pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:22.3pt; vertical-align:top; width:77.9pt"><p>&nbsp;</p></td><td style="height:22.3pt; vertical-align:top; width:63.85pt"><p>&nbsp;</p></td><td style="height:22.3pt; vertical-align:top; width:56.7pt"><p style="margin-left:6.0pt; margin-right:5.65pt; text-align:center">&lt; 1/1000)</p></td><td style="height:22.3pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:22.3pt; vertical-align:top; width:63.75pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:67.65pt; vertical-align:top; width:73.8pt"><p>&nbsp;</p></td><td style="height:67.65pt; vertical-align:top; width:70.95pt"><p style="margin-left:5.35pt">Spotting*</p><p>&nbsp;</p><p style="margin-left:5.35pt; margin-right:6.25pt">Hypo- menorrhoea*</p></td><td style="height:67.65pt; vertical-align:top; width:77.9pt"><p>&nbsp;</p></td><td style="height:67.65pt; vertical-align:top; width:63.85pt"><p>&nbsp;</p></td><td style="height:67.65pt; vertical-align:top; width:56.7pt"><p>&nbsp;</p></td><td style="height:67.65pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:67.65pt; vertical-align:top; width:63.75pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:56.65pt; vertical-align:top; width:73.8pt"><p style="margin-left:5.35pt">General disorders and administration site conditions</p></td><td style="height:56.65pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:56.65pt; vertical-align:top; width:77.9pt"><p style="margin-left:5.35pt">Oedema</p></td><td style="height:56.65pt; vertical-align:top; width:63.85pt"><p>&nbsp;</p></td><td style="height:56.65pt; vertical-align:top; width:56.7pt"><p>&nbsp;</p></td><td style="height:56.65pt; vertical-align:top; width:70.95pt"><p>&nbsp;</p></td><td style="height:56.65pt; vertical-align:top; width:63.75pt"><p>&nbsp;</p></td></tr></tbody></table><p style="margin-left:11.85pt">* in the indication Endometriosis</p><p>&nbsp;</p><p style="margin-left:47.25pt"><u>Reporting of suspected adverse reactions</u></p><p style="margin-left:47.25pt; margin-right:16.7pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p style="margin-left:47.25pt; margin-right:16.7pt">&nbsp;</p><p style="margin-left:47.25pt; margin-right:16.7pt"><strong>To report any side effect(s):</strong></p><p style="margin-left:47.25pt; margin-right:16.7pt">The National Pharmacovigilance and Drug Safety Centre (NPC).</p><p style="margin-left:47.25pt; margin-right:16.7pt">Fax: + 966 - 11 - 205 - 7662.</p><p style="margin-left:47.25pt; margin-right:16.7pt">Call NPC at +966 - 11 - 2038222,</p><p style="margin-left:47.25pt; margin-right:16.7pt">Ext.: 2317 - 2356 - 2340.</p><p style="margin-left:47.25pt; margin-right:16.7pt">Reporting hotline: 19999.</p><p style="margin-left:47.25pt; margin-right:16.7pt">E - mail: npc.drug@sfda.gov.sa.</p><p style="margin-left:47.25pt; margin-right:16.7pt">Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been no reports of ill-effects from overdosage and treatment is generally unnecessary. There are no special antidotes, and treatment should be symptomatic</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:47.25pt; margin-right:20.15pt">Pharmacotherapeutic group: sex hormones and modulators of the genital system, progestogens; Estren derivatives</p><p style="margin-left:47.25pt">ATC Code: G03DC02</p><p>&nbsp;</p><p>Norethisterone has progestational actions similar to those of progesterone, but is a more potent inhibitor of ovulation and has weak oestrogenic and androgenic properties. It is used to treat a number of disorders of the menstrual cycle</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:47.25pt; margin-right:20.15pt">Norethisterone is absorbed from the gastro-intestinal tract and its effects last for at least 24 hours. It is excreted in the urine.</p><p>&nbsp;</p><p style="margin-left:68.6pt; text-indent:-21.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Metabolism</p><p>&nbsp;</p><p style="margin-left:47.25pt; margin-right:16.7pt">Norethisterone is partly metabolised to ethinylestradiol after oral administration of norethisterone or norethisterone acetate in humans. This conversion results in an equivalent dose of about 4-6</p><p>&micro;g ethinylestradiol per 1 mg orally administered norethisterone / norethisterone acetate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:47.25pt; margin-right:19.95pt; text-align:justify">Non-clinical data on norethisterone or its esters reveal no special risk for humans based on conventional studies of repeated dose toxicity, genotoxicity and carcinogenic potential which is not already included in other relevant sections. However, it should be kept in mind that sexual steroids might stimulate the growth of hormone-dependent tissues and tumours.</p><p style="margin-left:47.25pt; margin-right:19.95pt; text-align:justify">Reproduction toxicity studies showed the risk of masculinisation in female fetuses when administered at high doses at the time of the development of the external genitalia. Since epidemiological studies show that this effect is relevant in humans after high doses, it must be stated that Primolut N may provoke signs of virilisation in female fetuses if administered during the hormone-sensitive stage of somatic sexual differentiation (from day 45 of pregnancy onwards). Apart from this, no indications of teratogenic effects were obtained from the studies.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:48.3pt; margin-right:385.0pt">lactose maize starch</p><p style="margin-left:48.3pt; text-align:justify">magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:48.3pt; margin-right:0in; text-align:justify">Not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:48.3pt; text-align:justify">Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:48.3pt; text-align:justify">30 tablets in aluminium/ PVC blisters in a carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the reach of children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bayer AG,
Kaiser-Wilhelm-Allee 1
51373 Leverkusen, Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                13 December 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>